|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pelucchi C, Bosetti C, Negri E, Malvezzi M
and La Vecchia C: Mechanisms of disease: The epidemiology of
bladder cancer. Nat Clin Pract Urol. 3:327–340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oosterlinck W, Lobel B, Jakse G, Malmström
PU, Stöckle M and Sternberg C: Guidelines on bladder cancer. Eur
Urol. 41:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loehrer PJ Sr, Einhorn LH, Elson PJ,
Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R,
Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin
alone or in combination with methotrexate, vinblastine and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 10:1066–1073.
1992.PubMed/NCBI
|
|
5
|
Sternberg CN, de Mulder PH, Schornagel JH,
Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van
Groeningen CJ, de Balincourt C, et al: Randomized phase III trial
of high-dose-intensity methotrexate, vinblastine, doxorubicin and
cisplatin (MVAC) chemotherapy and recombinant human granulocyte
colony-stimulating factor versus classic MVAC in advanced
urothelial tract tumors: European organization for research and
treatment of cancer protocol no. 30924. J Clin Oncol. 19:2638–2646.
2001.PubMed/NCBI
|
|
6
|
Von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
7
|
Von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bellmunt J, von der Maase H, Mead GM,
Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C,
Paz-Ares L, Laufman LR, et al: Randomized phase III study comparing
paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in
patients with locally advanced or metastatic urothelial cancer
without prior systemic therapy: EORTC intergroup study 30987. J
Clin Oncol. 30:1107–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dogliotti L, Cartenì G, Siena S, Bertetto
O, Martoni A, Bono A, Amadori D, Onat H and Marini L: Gemcitabine
plus cisplatin versus gemcitabine plus carboplatin as first-line
chemotherapy in advanced transitional cell carcinoma of the
urothelium: Results of a randomized phase 2 trial. Eur Urol.
52:134–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meluch AA, Greco FA, Burris HA III,
O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V and
Hainsworth JD: Paclitaxel and gemcitabine chemotherapy for advanced
transitional-cell carcinoma of the urothelial tract: A phase II
trial of the Minnie pearl cancer research network. J Clin Oncol.
19:3018–3024. 2001.PubMed/NCBI
|
|
11
|
Gitlitz BJ, Baker C, Chapman Y, Allen HJ,
Bosserman LD, Patel R, Sanchez JD, Shapiro RM and Figlin RA: A
phase II study of gemcitabine and docetaxel therapy in patients
with advanced urothelial carcinoma. Cancer. 98:1863–1869. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bellmunt J, Théodore C, Demkov T, Komyakov
B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A,
Karyakin O, et al: Phase III trial of vinflunine plus best
supportive care compared with best supportive care alone after a
platinum-containing regimen in patients with advanced transitional
cell carcinoma of the urothelial tract. J Clin Oncol. 27:4454–4461.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn
DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ and Kaufman
DS: Phase II study of pemetrexed for second-line treatment of
transitional cell cancer of the urothelium. J Clin Oncol.
24:3451–3457. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vaughn DJ, Broome CM, Hussain M, Gutheil
JC and Markowitz AB: Phase II trial of weekly paclitaxel in
patients with previously treated advanced urothelial cancer. J Clin
Oncol. 20:937–940. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McCaffrey JA, Hilton S, Mazumdar M, Sadan
S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel
in patients with advanced or metastatic transitional-cell
carcinoma. J Clin Oncol. 15:1853–1857. 1997.PubMed/NCBI
|
|
16
|
Lorusso V, Pollera CF, Antimi M, Luporini
G, Gridelli C, Frassineti GL, Oliva C, Pacini M and De Lena M: A
phase II study of gemcitabine in patients with transitional cell
carcinoma of the urinary tract previously treated with platinum.
Italian co-operative group on bladder cancer. Eur J Cancer.
34:1208–1212. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pronzato P, Vigani A, Pensa F, Vanoli M,
Tani F and Vaira F: Second line chemotherapy with ifosfamide as
outpatient treatment for advanced bladder cancer. Am J Clin Oncol.
20:519–521. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bellmunt J, Cos J, Clèries R, Pérez M,
Ribas A, Eres N, Murio JE, Margarit C and Baselga J: Feasibility
trial of methotrexate-paclitaxel as a second-line therapy in
advanced urothelial cancer. Cancer Invest. 20:673–685. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krege S, Rembrink V, Börgermann C, Otto T
and Rübben H: Docetaxel and ifosfamide as second-line treatment for
patients with advanced or metastatic urothelial cancer after
failure of platinum chemotherapy: A phase 2 study. J Urol.
165:67–71. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin CC, Hsu CH, Huang CY, Keng HY, Tsai
YC, Huang KH, Cheng AL and Pu YS: Gemcitabine and ifosfamide as a
second-line treatment for cisplatin-refractory metastatic
urothelial carcinoma: A phase II study. Anticancer Drugs.
18:487–491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soga N, Onishi T, Arima K and Sugimura Y:
Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy
for advanced platinum resistant urothelial cancer in Japanese
cases. Int J Urol. 14:828–832. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suyama T, Ueda T, Fukasawa S, Imamura Y,
Nakamura K, Miyasaka K, Sazuka T, Egoshi K, Nihei N, Hamano M, et
al: Combination of gemcitabine and paclitaxel as second-line
chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol.
39:244–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albers P, Park SI, Niegisch G, Fechner G,
Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R and
Siener R: AUO Bladder Cancer Group: Randomized phase III trial of
2nd line gemcitabine and paclitaxel chemotherapy in patients with
advanced bladder cancer: short-term versus prolonged treatment
[German Association of Urological Oncology (AUO) trial AB 20/99].
Ann Oncol. 22:288–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bajorin DF: Paclitaxel in the treatment of
advanced urothelial cancer. Oncology (Williston Park). 14:43–52;
discussion 58. 2000.PubMed/NCBI
|
|
25
|
Raghavan D: Progress in the chemotherapy
of metastatic cancer of the urinary tract. Cancer. 97(Suppl 8):
S2050–S2055. 2003. View Article : Google Scholar
|
|
26
|
Papamichael D, Gallagher CJ, Oliver RT,
Johnson PW and Waxman J: Phase ii study of paclitaxel in pretreated
patients with locally advanced/metastatic cancer of the bladder and
ureter. Br J Cancer. 75:606–607. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marchetti P, Urien S, Cappellini GA,
Ronzino G and Ficorella C: Weekly administration of paclitaxel:
Theoretical and clinical basis. Crit Rev Oncol Hematol. 44(Suppl):
S3–S13. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Markman M: Management of toxicities
associated with the administration of taxanes. Expert Opin Drug
Saf. 2:141–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perez EA, et al: A large phase II study of
paclitaxel administered as a weekly one hour infusion in patients
with metastatic breast cancer. Proc Am Soc Clin Onco.
18:126a1999.
|
|
30
|
Fennely D, Aghajanian C, Shapiro F,
O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L and Spriggs
D: Phase I and pharmacologic study of paclitaxel administered
weekly in patients with relapsed ovarian cancer. J Clin Oncol.
15:187–192. 1997.PubMed/NCBI
|
|
31
|
Joly F, Houédé N, Noal S, Chevreau C,
Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M and
Culine S: Do patients with advanced urothelial carcinoma benefit
from weekly paclitaxel chemotherapy? A GEUG phase II study. Clin
Genitourin Cancer. 7:E28–E33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Raghavan D and Huben R: Management of
bladder cancer. Curr Probl Cancer. 19:1–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim
YT and Lee K: Pre-treatment neutrophil to lymphocyte ratio is
elevated in epithelial ovarian cancer and predicts survival after
treatment. Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of
neutrophils to lymphocytes is associated with patient prognosis in
advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gomez D, Farid S, Malik HZ, Young AL,
Toogood GJ, Lodge JP and Prasad KR: Preoperative
neutrophil-to-lymphocyte ratio as a prognostic predictor after
curative resection for hepatocellular carcinoma. World J Surg.
32:1757–1762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarraf KM, Belcher E, Raevsky E, Nicholson
AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its
association with survival after complete resection in non-small
cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gondo T, Nakashima J, Ohno Y, Choichiro O,
Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T and Tachibana
M: Prognostic value of neutrophil-to-lymphocyte ratio and
establishment of novel pre-operative risk stratification model in
bladder cancer patients treated with radical cystectomy. Urology.
79:1085–1091. 2012. View Article : Google Scholar : PubMed/NCBI
|
